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Abstract: Melanoma can be classified based on the detection of relevant oncogenic driver mutations.
These mutations partially determine a patient’s treatment options. MEK inhibitors have demonstrated
little efficacy in patients with NRAS-mutated melanoma owing to primary and secondary resistance. We
report two patients with NRAS-mutant metastatic melanoma with long-term response to intermittent
MEK-inhibitor binimetinib therapy. Intermittent dosing schedules could play a key role in preventing
resistance to targeted therapy. This article highlights the efficacy of an intermittent dosing schedule, tox-
icities associated with binimetinib, and possible mechanisms preventing resistance in targeted therapy.
Intermittent MEK-inhibitor therapy may be considered in patients with NRAS-mutated melanoma that
have failed all standard therapies. KEY POINTS: Melanomas harbor NRAS mutations in 10%-30% of the
cases. These mutations promote hyperactivation of the MAPK pathway, leading to proliferation and pro-
longed survival of tumor cells. Currently, drugs directly targeting NRAS are not available. Downstream
inhibition of the MAPK pathway can be considered as a therapeutic option after immunotherapeutic
failure. Intermittent administration of kinase inhibitors might be the way to partially overcome the de-
velopment of drug resistance by (a) inducing a fitness deficit for drug-resistant cells on treatment break,
(b) increasing the immunogenicity, and (c) inducing apoptosis and cell cycle arrest. It also enhances ex-
pression of numerous immunomodulating molecules, and reduction of immunosuppressive factors, which
suggests better access of the immune system to the tumor.
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ABSTRACT
Melanoma can be classified based on the detection of rele-
vant oncogenic driver mutations. These mutations partially
determine a patient’s treatment options. MEK inhibitors
have demonstrated little efficacy in patients with NRAS-
mutated melanoma owing to primary and secondary resis-
tance. We report two patients with NRAS-mutant meta-
static melanoma with long-term response to intermittent
MEK-inhibitor binimetinib therapy. Intermittent dosing
schedules could play a key role in preventing resistance to
targeted therapy. This article highlights the efficacy of an
intermittent dosing schedule, toxicities associated with
binimetinib, and possible mechanisms preventing resistance
in targeted therapy. Intermittent MEK-inhibitor therapy
may be considered in patients with NRAS-mutated mela-
noma that have failed all standard therapies. The
Oncologist 2020;25:e1593–e1597
KEY POINTS
• Melanomas harbor NRAS mutations in 10%–30% of the cases. These mutations promote hyperactivation of the MAPK
pathway, leading to proliferation and prolonged survival of tumor cells.
• Currently, drugs directly targeting NRAS are not available. Downstream inhibition of the MAPK pathway can be consid-
ered as a therapeutic option after immunotherapeutic failure.
• Intermittent administration of kinase inhibitors might be the way to partially overcome the development of drug
resistance by (a) inducing a fitness deficit for drug-resistant cells on treatment break, (b) increasing the immuno-
genicity, and (c) inducing apoptosis and cell cycle arrest. It also enhances expression of numerous
immunomodulating molecules, and reduction of immunosuppressive factors, which suggests better access of the
immune system to the tumor.
PATIENT STORIES
Patient 1
A 71-year-old female presented with multiple subcutaneous
in-transit metastases on the shin after resection of a mela-
noma on her right lower leg (Breslow 1.1 mm). Her sentinel
lymph nodes were negative. Several surgical procedures
were performed because of local relapses. The mutational
analysis of an in-transit metastasis by polymerase chain
reaction (PCR) and sequencing analysis detected a NRAS
mutation (p.Q61R in Exon 3). Despite treatment with anti–
cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) anti-
bodies (ipilimumab 200 mg intravenously, four infusions),
the disease progressed (locoregional lymph node involve-
ment and in-transit soft tissue metastasis up to 4.5 cm in
size). As anti–programmed cell death protein 1 (PD-1)
blockade was not available at the time, the patient was
enrolled in a clinical trial investigating binimetinib (45-mg
tablets p.o. b.i.d.; NCT01763164) in March 2015. Binimetinib
was stopped after 6 weeks of treatment owing to myalgia
and severe creatine phosphokinase (CPK) elevation grade (G)
3. The patient also developed acneiform dermatitis G2, bilat-
eral retinopathy G1, and eye pressure elevation G2. All
adverse events (AEs) resolved when binimetinib was
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withheld. On resumption of binimetinib, the same AEs
recurred after 3–6 weeks. Consequently, a dose reduction
(30 mg b.i.d.) and intermittent treatment (3 weeks on and
10 days off) schedule was trialed. On this regimen, CPK eleva-
tion fluctuated between G1 and G3. The acneiform dermatitis
peaked to G2 at the end of each treatment phase but settled
between dosing. Both retinopathy and elevated eye pressure
were never symptomatic but present on ophthalmic review. A
combination of a beta-blocker and a carbonic anhydrase inhib-
itor (cosopt eye drops) led to improvement of the eye pres-
sure. The patient did not experience myalgia.
Patient 2
A 75-year-old male presented with a melanoma (Breslow
0.95 mm) on the trunk. He developed right axillary lymph
node metastasis developed right lymph node metastasis
axillary in December 2013. Mutational analysis by PCR
and sequencing revealed a NRAS mutation (p.Q61K in
Exon 3). Within 6 months, the patient developed hilar
lymph node metastasis of 3.4 cm, lung and soft tissue
metastases (stage IV disease) (Figure 1). In July 2014,
binimetinib (45-mg tablets b.i.d.) was started (NCT01763164).
Immunotherapy was kept as salvage therapy. Four weeks into
therapy, treatment had to be suspended because of CPK
elevation G4. The patient experienced facial acneiform derma-
titis G2 and retinopathy G1, but no myalgias. A 2-weeks-on
and 1-week-off schedule with reduced dose (30 mg b.i.d.) was
commenced. With this regimen, CPK elevation was between
G1 and G3, acneiform dermatitis between G1 and G2, and the
retinopathy between G0 and G1. Within the first year of treat-
ment, the tumor burden continuously decreased with overall
partial response. By April 2017, all lesions had disappeared or
shrunk to a maximum of 5 mm and remained stable. In
August 2018, binimetinib was ceased owing to right central
retinal vein thrombosis. The visual disturbance improved and
eventually returned to normal with two intravitreal anti–
vascular endothelial growth factor injections and eye
pressure–reducing drops (dorzolamide and timolol).
MOLECULAR TUMOR BOARD
Melanoma and Tumor Biology
Development of melanoma can be triggered by activating
oncogenes or inactivating tumor-suppressor genes through
specific mutations. Some of the most important signaling
pathways involved in the pathogenesis of melanoma
include MAPK, PI3K/PTEN/AKT, and MITF [1].
Cutaneous melanomas can be divided into four genomic
subtypes: BRAF, RAS, NF1, and triple-WT melanomas [2].
In The Cancer Genome Atlas (TCGA), NRAS somatic
mutations were present in 28% of the analyzed samples [2].
NRAS and BRAF mutations are thought to be often mutually
exclusive. However, the presence of both mutations in one
cell line was proved [3]. Either of them is sufficient to pro-
mote hyperactivation of the MAPK pathway, leading to pro-
liferation and prolonged survival of tumor cells.
Genotyping Results and Interpretation of the
Molecular Results
In the presented cases, NRAS mutations (p.Q61K in Exon
3 and p.Q61R in Exon 3) were detected by both PCR and
sequencing. BRAF mutation was not present.
The most common NRAS mutation in melanoma
(occurring in more than 80% of NRAS-mutated samples) is
a substitution of glutamine with arginine or lysine at posi-
tion p.61 (NRASQ61R/K/L) as a result of the c.181C > A
Figure 1. Representative transverse chest computed tomography sections of Patient 2. Left hilar metastasis measuring 3.4 × 2.6 cm
at baseline (A) showing complete remission under intermittent therapy with binimetinib (B). Mediastinal metastasis of 1.5 × 1 cm
adjacent to the esophagus (C) was not detectable at the end of therapy in August 2018 (D).
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transversion (38%) of the c.182A > G transition (34%) or of
the c.182A > T transversion (10%) in exon 3 of the gene,
respectively [4]. Codon 61 mutations are associated with
locking of the RAS protein into its activating conformation
and impaired GTPase activity [5], leading to activated RAS
signaling (MAPK pathway) with consecutive cell growth,
motility, and survival, thereby enhancing tumor growth
[6]. NRAS mutation not only activates the MAPK pathway,
but can also trigger activation of the phosphatidylinositol
3-kinase/protein kinase B (PI3K/AKT) pathway and other
survival signaling pathways [7].
Functional and Clinical Significance of NRAS
Mutation in Melanoma
NRAS mutation is considered the second most common
oncogenic driver mutation in melanoma. Compared with
BRAF-mutated or WT NRAS melanoma, there are conflicting
data regarding the importance of NRAS mutations in out-
comes to new therapies, particularly checkpoint inhibitors.
Potential Strategies to Target the Pathway and
Implications for Clinical Practice
Currently, there are no drugs that target NRAS. Downstream
inhibition of the MAPK pathway can be considered as a
therapeutic option after immunotherapeutic failure.
Binimetinib, a selective inhibitor of mitogen-activated pro-
tein kinase (MEK1 and 2), demonstrated some benefit in
patients with NRAS-mutated melanoma (median progression-
free survival [PFS] 3.7 months, 95% confidence interval
[CI] 2.5–5.4) [8]. In the pivotal trial comparing dacarbazine and
binimetinib, median PFS for patients with MEK inhibitor–
treated NRAS-mutant melanoma was 2.8 months (95% CI
2.8–3.6) versus 1.5 months (95% CI 1.5–1.7) in the dacarbazine
group [9]. Unfortunately, most patients develop resistance
within the first year [10].
Common AEs of MEK inhibitors include diarrhea (G1–2
39%, G3–4 1%), acneiform dermatitis (G1–2 33%, G3–4 3%),
increased CPK (G1–2 23%, G3–4 19%), and various ocular
events such as retinal pigment epithelial detachment (reti-
nopathy; G1–2 32%, G3–4 1%) and retinal vein occlusion
(G1–4 2%) [9].
In view of the modest outcomes and the AEs, MEK inhibi-
tors are not routinely used for NRAS-mutant melanomas.
Despite low clinical efficacy, we report two cases of
long-term response to binimetinib treated with an intermit-
tent dosing schedule. Intermittent dosing was well tolerated
and toxicity was manageable. Yaeger et al. also reported
long-term response to intermittent MEK-inhibitor treatment
in a patient with melanoma with RAF1 mutation [11].
Intermittent MEK Inhibition as a Possible Mechanism
Preventing Resistance
Most tyrosine kinase–resistant tumor cells remain depen-
dent on MAPK pathway signaling and rely on ERK (extracel-
lular signal-regulated kinase) reactivation [12, 13]. Although
reliant on oncogenes (MAPK pathway and ERK signaling),
resistant tumor cells experience a fitness deficit in the
absence of the drug. They can induce apoptosis and cell
cycle arrest [13]. This is observed with both inhibition and
hyperactivation of the MAPK pathway leading to an
excessive MEK–ERK signaling [14]. It seems that melanoma
cells require a specific level of activated ERK for optimal
tumor growth. Drug-resistant tumor cells have a selective
disadvantage in the absence of the drug, leading to
regrowth of drug-sensitive tumor cells during drug holiday
[15]. Moreover, MITF (microphthalmia-associated transcrip-
tion factor), an important regulator of melanoma cell prolif-
eration and survival, is strongly linked to the MAPK
pathway. In MEK inhibitor–resistant melanoma cells, MITF
expression can be highly upregulated, whereas strong acti-
vation of MAPK signaling will reduce MITF protein levels
through degradation [16].
We propose that the dosing interval during intermittent
therapy targets drug-sensitive tumor cells and the off inter-
val drives drug-resistant tumor cells into cell cycle arrest
and apoptosis.
Different data support the strategy of intermittent dos-
ing for MEK-inhibitor therapy. First, MEK inhibitors lead to
an initial increase of HLA-1 and HLA-2, enhanced expression
of numerous immunomodulating molecules, and reduction
of immunosuppressive factors such as IL1A, IL8,
programmed death-ligand 1 (PD-L1), and others [17]. Higher
immunogenicity at the beginning of treatment would sug-
gest more efficient antitumor response. Second, after a lon-
ger exposure to MEK inhibitor, melanoma cells can switch
phenotype into more invasive cell behavior. Zipser et al.
demonstrated a phenotype switch in MITF-expressing
tumor cells with an activated MAPK pathway after 2 weeks
of treatment. This was characterized by a change in mor-
phology, increased invasiveness, and a decline in expression
of melanocytic differentiation antigens. [18] Third, Deken
et al. reported a high influx of T cells within the first week
and lesser presence of T cells later on in a mouse model
treated with kinase inhibitors [19]. An enrichment of
tumor-infiltrating, antigen-specific CD8+ effector T cells in
the MEK inhibitor–treated mice has also been demon-
strated [20]. Consequently, this implies a more effective
access of the immune system to the tumor at the beginning
of the treatment.
These alterations give reasonable justification to
assume that immunogenicity could be elevated at the
beginning of MAPK pathway inhibition and reduced
after long-term exposure. Intermittent administration
of kinase inhibitors may overcome this problem [21].
Consistent with our hypothesis, Choi et al. recently
demonstrated that pulsatile, rather than continuous,
treatment with MEK inhibitors in murine models can
maintain T-cell activity better and prolong survival in
KRAS mutant cancer. This effect is further enhanced
when combined with immunotherapy [22].
Continuous MEK-inhibitor administration combined with
anti–PD-L1 inhibitor atezolizumab failed in a recent clinical
study in humans [23]. Based on our experience, this study
protocol should be repeated with an intermittent MEK-
inhibitor dosing.
Another strategy to optimize tumor apoptosis is a combi-
nation of MEK inhibitors and CDK4/6 inhibitors. Teh et al.
demonstrated in an in vivo study a more effective tumor
inhibition with less toxicity on an intermittent dosing
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schedule (in this case continuous MEK inhibition with inter-




The patient’s tumor burden steadily decreased in the first
6 months of treatment and remained stable for more than
4 years. Side effects were well tolerated with the intermit-
tent dosing schedule. In April 2019, two progressive nodules
were detected on the right shin leading to end of treatment
because of progressive disease. A next-generation sequencing–
based test (FoundationOne CDx, Foundation Medicine Inc.
Cambridge, MA, USA) of the excised metastasis confirmed
NRAS Q61R mutation as well as CDKN2A/B loss, EED R441 alter-
ation, MTAP loss, and TERT promoter alteration 1146 C > T. The
tumor mutational burden was intermediate with 11 mutations
per megabase. NRAS mutations with CDKN2A/B loss and TERT
promoter alterations are likely present at baseline based on
their high prevalence in primary samples [2]. Whereas the role
of MTPA loss in melanoma is not clearly characterized, the EED
R441 alteration might favor resistance by EZH2-mediated epige-
netic changes [25]. But as no serial biopsies were performed,
we can only speculate on the resistance mechanisms.
Immunotherapy with anti–PD1-inhibitor nivolumab (six
infusions of 240 mg intravenously every 2 weeks) was started
in June 2019. Despite this, the patient’s condition progressed.
Combined intermittent binimetinib (Mektovi Pfizer, New York)
with nivolumab initiated in September 2019 finally resulted in
complete metabolic response by June 2020.
Patient 2
No further therapy was required as regular imaging by posi-
tron emission tomography–computed tomography demon-
strated complete metabolic response. This prolonged
response is unusual in the landscape of targeted therapy.
Supportive factors might be the small tumor burden and
normal LDH at therapy start, as well as favorable organ
involvement (lymph node, lung) [9].
CONCLUSION
NRAS-mutated melanomas have fewer treatment options
compared with BRAF-mutated melanomas. We report two
patients with NRAS-mutant melanoma with long-term
response on an intermittent MEK-inhibitor treatment with
reduced dosing. Both patients did not develop resistance
for more than 3 years, and the regimen was well tolerated
with manageable side effects. Intermittent therapy may be
key to achieving better responses, reducing side effects,
and delaying drug resistance. Larger-cohort studies are
required to investigate these findings.
AUTHOR CONTRIBUTIONS
Conception/design: Reinhard Dummer, Simone M. Goldinger
Provision of study material or patients: Alexandra Valeska Matter, Sara
Micaletto, Ursula Urner-Bloch, Reinhard Dummer
Collection and/or assembly of data: Alexandra Valeska Matter, Sara
Micaletto, Ursula Urner-Bloch, Reinhard Dummer, Simone M. Goldinger
Data analysis and interpretation: Alexandra Valeska Matter, Sara Micaletto,
Ursula Urner-Bloch, Reinhard Dummer, Simone M. Goldinger
Manuscript writing: Alexandra Valeska Matter, Simone M. Goldinger
Final approval of manuscript: Alexandra Valeska Matter, Sara Micaletto,
Ursula Urner-Bloch, Reinhard Dummer, Simone M. Goldinger
DISCLOSURES
Richard Dummer: Novartis, Merck Sharp & Dohme, Bristol-Myers
Squibb, Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi,
Catalym, Second Genome (C/A). The other authors indicated no
financial relationships.
(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert
testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/
inventor/patent holder; (SAB) Scientific advisory board
GLOSSARY OF GENOMIC TERMS AND NOMENCLATURE
AKT: protein kinase B
BRAF: v-raf murine sarcoma viral oncogene homolog B
CDKN2A/B: cyclin-dependent kinase inhibitor 2A/B
EED: embryonic ectoderm development
ERK: extracellular signal-regulated kinase
HLA: human leukocyte antigens, also called major histocompatibility
complex (MHC)
KRAS: Kirsten rat sarcoma viral oncogene homolog
MAPK: mitogen-activated protein kinases
MEK: mitogen-activated protein kinase kinase
MITF: microphthalmia transcription factor
MTAP: methylthioadenosine phosphorylase
NRAS: neuroblastoma RAS viral oncogene homolog
NF1: neurofibromin 1
RAS: rat sarcoma
PI3K: phosphatidylinositol 3-kinase/ protein kinase B
PTEN: phosphatase and tensin homologue
TCGA: The Cancer Genome Atlas
TERT: telomerase reverse transcriptase
WT: wildtype
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